Ovarian Cancer Is A Misnomer And Could Be Easily Prevented

According to experts, 80% of all ovarian cancer cases — including most fatal cases — are actually cancer of the fallopian tubes. The risk of getting ovarian cancer can be reduced by nearly 80% when the tubes are removed — a five-minute procedure that can be done as part of many abdominal surgeries, The New York Times reported. The American Cancer Society plans to launch a national awareness campaign next year.

The New York Times: There’s A Way To Prevent Ovarian Cancer. Few Know About It

Kira Wynn will do almost anything to avoid ovarian cancer, which killed her mother. “My mom thought she’d pulled a muscle in her side,” Ms. Wynn said. Her mother’s doctor, she added, “told her to do physical therapy.” As is often the case with ovarian cancer, Ms. Wynn’s mother’s disease was already at an advanced stage when she was diagnosed. She died 10 months later. (Kolata, 7/28)

Stat: FDA Staff Reiterate Concerns About Replimmune Skin Cancer Treatment

Regulators at the Food and Drug Administration have reiterated concerns that Replimune does not have adequate data to support an approval of its investigational skin cancer treatment, as the biotech tries for the third time to seek clearance for its highly controversial drug. (Chen and Herper, 7/28)

MedPage Today: FDA Staff Unconvinced Drug For Melanoma Shows Benefit

Another attempt to win accelerated approval for RP1 (vusolimogene oderparepvec) -- a melanoma drug candidate that's already been rejected twice by the FDA -- could face tough going at a meeting of FDA's outside experts this week. In a briefing document published in advance of Thursday's meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee, FDA staff wrote that the phase II single-arm IGNYTE study -- submitted by Replimune to support accelerated approval of RP1 in combination with nivolumab (Opdivo) for the treatment of advanced melanoma -- was not "an adequate and well-controlled investigation that demonstrates substantial evidence of effectiveness." (Bassett, 7/28)

On ALS, graft loss, diabetes, and cardiovascular risks —

Newsweek: One Simple Test May Detect ALS Years Before It Starts

A discovery in the blood could bring researchers one step closer to a long-sought goal in the fight against amyotrophic lateral sclerosis (ALS). Scientists have identified a group of proteins that begin to change months—or even years—before symptoms of the neurodegenerative disease appear, raising hopes that people at risk could one day be treated before irreversible nerve damage occurs. (Notarantonio, 7/28)

Trump 2.0

Public Health

Audio Reports

Special Reports

More Topics